Opus Genetics (IRD) Set to Post Quarterly Earnings on Wednesday

Opus Genetics (NASDAQ:IRD) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Opus Genetics to post earnings of ($0.14) per share and revenue of $1.55 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Opus Genetics (NASDAQ:IRD) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, analysts expect Opus Genetics to post ($0.97) EPS for the current fiscal year and ($0.70) EPS for the next fiscal year.

Opus Genetics Stock Up 6.2%

Shares of Opus Genetics stock opened at $3.93 on Wednesday. Opus Genetics has a 52 week low of $1.70 and a 52 week high of $7.07. The business’s fifty day simple moving average is $4.46 and its 200-day simple moving average is $4.17.

Analysts Set New Price Targets

IRD has been the topic of several research analyst reports. Oppenheimer boosted their price objective on shares of Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. JonesTrading lifted their target price on shares of Opus Genetics from $10.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of Opus Genetics in a research report on Wednesday, September 9th. Chardan Capital restated a “buy” rating and set a $16.00 price target on shares of Opus Genetics in a research note on Thursday, October 22nd. Finally, Citizens Jmp restated a “market outperform” rating and set a $17.00 price target on shares of Opus Genetics in a research report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.71.

Insider Buying and Selling at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 556,000 shares of Opus Genetics stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total value of $2,757,760.00. Following the completion of the transaction, the director directly owned 3,236,171 shares in the company, valued at approximately $16,051,408.16. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO George Magrath sold 9,591 shares of the company’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.58, for a total value of $34,335.78. Following the sale, the chief executive officer owned 2,038,894 shares in the company, valued at approximately $7,299,240.52. This trade represents a 0.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 645,547 shares of company stock worth $3,103,375 over the last ninety days. Company insiders own 11.70% of the company’s stock.

About Opus Genetics

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss and blindness. The company’s research is aimed at addressing the underlying genetic causes of these conditions rather than treating only their symptoms.

Its pipeline includes investigational ophthalmic gene therapies designed for specific IRD-causing mutations, including programs targeting conditions associated with the NR2E3 and BEST1 genes.